A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin.

Trial Profile

A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2014

At a glance

  • Drugs Telavancin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Apr 2011 Actual end date (1 Feb 2011) added as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top